Forty Seven (FTSV) Lowered to Hold at ValuEngine
ValuEngine lowered shares of Forty Seven (NASDAQ:FTSV) from a buy rating to a hold rating in a research report released on Monday morning.
A number of other research firms also recently commented on FTSV. HC Wainwright began coverage on Forty Seven in a report on Sunday, December 9th. They issued a buy rating and a $17.66 price objective on the stock. Zacks Investment Research upgraded Forty Seven from a sell rating to a hold rating in a report on Thursday, October 4th. Finally, Morgan Stanley increased their price objective on Forty Seven from $25.00 to $26.00 and gave the company an overweight rating in a report on Thursday, October 11th. Two equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. The company presently has a consensus rating of Buy and an average price target of $24.93.
FTSV opened at $21.11 on Monday. Forty Seven has a one year low of $12.02 and a one year high of $23.83.
A number of large investors have recently added to or reduced their stakes in the stock. Point72 Hong Kong Ltd purchased a new position in Forty Seven during the 2nd quarter worth approximately $120,000. Janus Henderson Group PLC purchased a new position in Forty Seven during the 2nd quarter worth approximately $160,000. DAFNA Capital Management LLC purchased a new position in Forty Seven during the 2nd quarter worth approximately $160,000. Waddell & Reed Financial Inc. purchased a new position in Forty Seven during the 2nd quarter worth approximately $160,000. Finally, Teachers Advisors LLC purchased a new position in Forty Seven during the 3rd quarter worth approximately $157,000. Hedge funds and other institutional investors own 41.44% of the company’s stock.
About Forty Seven
Forty Seven Inc, a clinical-stage immuno-oncology company, focuses on developing therapies to activate macrophages for the treatment of cancer. It is developing 5F9, a humanized IgG4 subclass monoclonal antibody against CD47 that is in Phase 1b/2 clinical trials used for the treatment of cancer; and FSI-189, an antibody that binds to SIRPa for the treatment of solid tumors.
Read More: Investing strategies using the yield curve
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Forty Seven Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Forty Seven and related companies with MarketBeat.com's FREE daily email newsletter.